Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Blonde

Showing results (81-90 of 144) with videos related to

Pageof 15
Sort By:
Diabetes, Obesity & Metabolism|March 8, 2019
Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort studyTimothy S Bailey, Fang L Zhou, Rishab A Gupta, et al.
Diabetes, Obesity & Metabolism|February 10, 2021
Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screeningJulio Rosenstock, Lawrence Blonde, Vanita R Aroda, et al.
Diabetes/Metabolism Research and Reviews|March 18, 2017
Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β indexRiccardo C Bonadonna, Lawrence Blonde, Mikhail Antsiferov, et al.
The American Journal of Managed Care|February 12, 2014
Attainment of diabetes-related quality measures with canagliflozin versus sitagliptinRobert A Bailey, C V Damaraju, Silas C Martin, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 21, 2018
Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal InsulinLawrence Blonde, Denis Raccah, Elisheva Lew, et al.
Diabetes Spectrum : a Publication of the American Diabetes Association|June 7, 2019
Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical PracticeLawrence Blonde, Stephen A Brunton, Pavan Chava, et al.
Lancet (London, England)|June 12, 2009
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)John B Buse, Julio Rosenstock, Giorgio Sesti, et al.
The Journal of Clinical Psychiatry|April 26, 2008
Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of careLawrence Blonde, Hong J Kan, Elane M Gutterman, et al.
Journal of Diabetes Research|June 11, 2015
Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes MellitusBindu Chamarthi, J Michael Gaziano, Lawrence Blonde, et al.
Diabetes Care|March 25, 2010
Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agentsJohn B Buse, Giorgio Sesti, Wolfgang E Schmidt, et al.
Pageof 15

Showing results (81-90 of 144) with videos related to

Sort By:
Pageof 15
Diabetes, Obesity & Metabolism|March 8, 2019
Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort studyTimothy S Bailey, Fang L Zhou, Rishab A Gupta, et al.
Diabetes, Obesity & Metabolism|February 10, 2021
Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screeningJulio Rosenstock, Lawrence Blonde, Vanita R Aroda, et al.
Diabetes/Metabolism Research and Reviews|March 18, 2017
Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β indexRiccardo C Bonadonna, Lawrence Blonde, Mikhail Antsiferov, et al.
The American Journal of Managed Care|February 12, 2014
Attainment of diabetes-related quality measures with canagliflozin versus sitagliptinRobert A Bailey, C V Damaraju, Silas C Martin, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 21, 2018
Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal InsulinLawrence Blonde, Denis Raccah, Elisheva Lew, et al.
Diabetes Spectrum : a Publication of the American Diabetes Association|June 7, 2019
Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical PracticeLawrence Blonde, Stephen A Brunton, Pavan Chava, et al.
Lancet (London, England)|June 12, 2009
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)John B Buse, Julio Rosenstock, Giorgio Sesti, et al.
The Journal of Clinical Psychiatry|April 26, 2008
Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of careLawrence Blonde, Hong J Kan, Elane M Gutterman, et al.
Journal of Diabetes Research|June 11, 2015
Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes MellitusBindu Chamarthi, J Michael Gaziano, Lawrence Blonde, et al.
Diabetes Care|March 25, 2010
Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agentsJohn B Buse, Giorgio Sesti, Wolfgang E Schmidt, et al.
Pageof 15